Janssen Reports New Data for BCMA CAR-T, Cilta-Cel, Showing Deep and Durable Responses in Patients with Relapsed or Refractory Multiple Myeloma

June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced new data for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed CAR-T therapy, demonstrated sustained efficacy and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM). Updated results from the Phase 1b/2 CARTITUDE-1 study (n=97) with a longer-term follow-up at a median of 18 months showed an overall response rate (ORR) of 98 percent, with 80 percent of patients achieving a stringent complete response (sCR), highlighting a deepening response over time (increasing from 67 percent presented at ASH 2020).1 These data also showed 66 percent of patients were progression free and alive at 18 months (95 percent Confidence Interval [CI], range, 54.9–75.0). The latest findings to be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, showed an overall survival (OS) of 81 percent (95 percent CI, range, 71.4–87.6)1 and response rates comparable across prespecified subgroups and lines of treatment (Abstract #8005).1 Data from the CARTITUDE-1 study supported the U.S. Food and Drug Administration Biologics License Application, which has recently been accepted for priority review. “The efficacy results observed in heavily pretreated patients with multiple myeloma receiving cilta-cel are remarkable,” said Saad Z. Usmani, M.D.†, Div...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news

Related Links:

New J. Chem., 2021, Accepted Manuscript DOI: 10.1039/D1NJ02448E, PaperYilong Tian, Wenhui Yi, Lei Bai, Xing Cheng, Tao Yi, Mingzhu Mu, Ping Zhang, Jinhai Si, Xun Hou, Jin Hou For most cancers, multimodal cancer synergistic therapy is far more effective than monotherapy. Herein, a multifunctional nanocarrier based on lentinan (LTN) in-situ functionalized molybdenum disulfide nanoflowers (MoS2@LTN NFs) is developed... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
New J. Chem., 2021, Advance Article DOI: 10.1039/D1NJ01509E, PaperLakshmi Kalyani Ruddaraju, Sarath Chandra Veerla, Venkata Ramana Murthy Kolapalli, Panduranga Naga Vijay Kumar Pallela, Veerabhadra Swamy Padavala, S. V. N. Pammi The novelty of the present work is thein-vitro andin vivo nano-antibitoic combinational therapy along within vitro anti-cancer and biocompatibility activities of green synthesized CuO NLs. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - New J. Chem. latest articles - Category: Chemistry Authors: Source Type: research
Chem. Commun., 2021, Accepted Manuscript DOI: 10.1039/D1CC03047G, CommunicationThanh Lam Bui, Ngoc Thanh Ho, Xuan Vuong Thi Thanh Ho, Dinh Nghi Ngo, Soon Hyuk Lim, Sang Jun Son, Seung Man Noh, Sang-Woo Joo Optical properties of anisotropic gold nanorod arrays inside anodic aluminium oxide substrates enhance the longitudinal absorption intensities and the hyperthermia cancer cell killing at 42.1 °C under photothermal laser exposures... The content of this RSS Feed (c) The Royal Society of Chemistry
Source: RSC - Chem. Commun. latest articles - Category: Chemistry Authors: Source Type: research
Advisers to government in Tokyo say Covid surge requires harsher measures, while Australian state of NSW announces 262 new casesFifth of Covid hospital admissions are aged 18-34, says NHS EnglandSydney Covid Delta variant outbreak ‘an epidemic of young people’Indonesia Covid deaths pass 100,000 as Delta overwhelms hospitalsUS disputes WHO call to delay Covid booster shots to help poorer nations‘They thought Covid only kills white people’: myths hinder jabs in DRC12.21pmBSTTokyo reported another large jump in virus cases on Thursday, again shattering records, as the government expanded restrictions t...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Coronavirus Infectious diseases Science World news Australia news Japan US news UK news Source Type: news
[New Zimbabwe] SCHOOL teachers say they can only return to work when they receive full Covid-19 vaccination.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
Raritan, N.J., June 12, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® (daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.[1] These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A c...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
This study evaluated the ability of teclistamab to induce cytotoxicity and T-cell activation.About TeclistamabTeclistamab is an investigational bispecific antibody targeting both BCMA and CD3. BCMA, B-cell maturation antigen, is expressed at high levels on multiple myeloma cells.[3],[4],[5],[6],[7] Teclistamab redirects CD3-positive T-cells to BCMA-expressing myeloma cells to induce cytotoxicity of the targeted cells.5,6 Results from preclinical studies demonstrate that teclistamab kills myeloma cell lines and bone marrow-derived myeloma cells from heavily pretreated patients.6 Teclistamab is currently being evaluated in a...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today longer-term results from the combined Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of ciltacabtagene autoleucel (cilta-cel), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of patients with relapsed and/or refractory multiple myeloma. These data, presented as an oral presentation at the American Society of Hematology (ASH) 2020 Annual Meeting (Abstract #177), continued to demonstrate a very high...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
More News: Allergy & Immunology | Anemia | Biotechnology | Brain | Calcium | Cancer | Cancer & Oncology | Cancer Vaccines | Cardiology | Cardiovascular | China Health | European Medicines Agency (EMA) | Food and Drug Administration (FDA) | Health Management | Heart | Hematology | Hypertension | Infectious Diseases | Learning | Legislation | Leukemia | Marketing | Myeloma | Neurology | Neuroscience | Oral Cancer | Orthopaedics | Pain | Pain Management | Pharmaceuticals | Politics | Pulmonary Hypertension | Revlimid | Science | Statistics | Study | Thrombocytopenia | Universities & Medical Training | Urology & Nephrology | Vaccines | Velcade | Women